search
Back to results

Stress Management Using an App to Improve Response With PDE5 Inhibitors in Men With Erectile Dysfunction.

Primary Purpose

Erectile Dysfunction

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Utilization of Serenita for Relaxation
Sponsored by
Eco Fusion
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Erectile Dysfunction focused on measuring Erectile Dysfunction

Eligibility Criteria

18 Years - 55 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Male ages 18-55 years old
  • Persistent mild to moderate ED on PDE5 inhibitors (Viagra, Cialis, Levitra, Stendra)
  • Understand English
  • Owns smartphone using either iPhone or Android
  • Able to understand the use of "Serenita" app
  • Willing to use Serenita app before sexual attempt
  • Willing to complete all study questionnaires Willing to perform sexual attempt for at least once a week until end of study.

Exclusion Criteria:

  • On testosterone replacement therapy
  • History of Peyronie's disease
  • Significant cardiac history (uncontrolled hypertension, cardiac arrhythmia, coronary artery disease, coronary bypass surgery)
  • Uncontrolled diabetes mellitus
  • History of prostate cancer
  • Poorly controlled, symptomatic, active medical problems (HIV, hepatitis, cancer, benign prostatic hypertrophy, alcohol or drug abuse, major depressive disorder)
  • Neurological or psychiatric disorder that would compromise the patient's ability to give informed consent or adhere to the requirements of the protocol

Sites / Locations

  • RMARecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Utilization of Serenita for Relaxation

Arm Description

Intervention is that Users continue to take their PDE-5 Inhibitor prior to sexual interaction and IN ADDITION Utilize the Serenita App daily and before any sexual encounters.

Outcomes

Primary Outcome Measures

Global Assessment Profile measured by a survey
If the treatment has improved their erectile function

Secondary Outcome Measures

Index of Erectile Function measured by a survey
if the treatment has improved erectile function

Full Information

First Posted
April 26, 2016
Last Updated
July 19, 2016
Sponsor
Eco Fusion
search

1. Study Identification

Unique Protocol Identification Number
NCT02757807
Brief Title
Stress Management Using an App to Improve Response With PDE5 Inhibitors in Men With Erectile Dysfunction.
Official Title
Stress Management Using an App to Improve Response With PDE5 Inhibitors in Men With Erectile Dysfunction.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Unknown status
Study Start Date
July 2016 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
December 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eco Fusion

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to determine if patients with ED taking PDE5 inhibitors (e.g. Viagra, CIalis, Levitra, Stendra) and experiencing performance anxiety will benefit using a user-friendly stress reducing phone app, Serenita. The study is internet based with no office visits.
Detailed Description
The etiology of erectile dysfunction (ED) has been investigated in many studies. Most often, ED is proposed to have a multifactorial etiology, with organic and/or psychogenic causal factors hypothesized to affect erectile function. Numerous studies show that Deep and Slow Breathing (DSB) reduces stress and anxiety. Since ED is multifactorial, many physicians rely solely on phosphodiesterase-5 (PDE-5) inhibitors to increase blood flow to the arteries to maintain an erection. Although it works in many patients, some patients can get overly anxious prior to sexual intercourse and not be able to produce or maintain an erection. While some patients may realize that DSB may improve their anxiety they don't know how to perform DSB properly. We hypothesize that by providing software interactivity on deep and slow breathing to this group of ED patients, may in turn help reduce their anxiety, thus, maximize the effect of PDE5 inhibitors. The app called "Serenita" for mobile phones, designed by Eco-Fusion will be utilized in this study. The app performs two functions: it detects stress and focus level and It guides the user through a personalized breathing exercise designed to reduce stress and increase focus. Breathing as a method to treat stress has three scientifically validated variations, the deep diaphragmatic breathing, used for centuries as part of Yoga which often refers as Yogic breathing, biofeedback breathing, a method in which the user sees in real-time how his breathing affects his stress level, and coherence breathing, a method that synchronizes breathing pace with heart rhythms. The technology embedded in Serenita app combines all three methods into a personalized guided breathing regimen. The app acquires data by turning the mobile phone's camera into a biomedical sensor which peers into a person's blood stream, obtaining heart rate, heart rate variability and breathing pace. Then the app processes the data obtained to assess user's stress and focus level. This study will utilize 6 standardized questionnaires to assess changes in patients' responses while using the app: Erectile Performance Anxiety Index (EPAI), which will ask questions that assess anxiety about being able to achieve or maintain an erection during sexual activity. International Index of Erectile Function (IIEF), which will ask questions about sexual encounters for the past four weeks. Psychological and Interpersonal Relationship Scales (PAIRS), which will ask questions about sexual self-confidence, time concerns and spontaneity with sexual encounters. Self-Esteem and Relationship (SEAR), which will ask questions about sexual relationship, confidence, stress ad perceived stress and overall sexual relationship for the past four weeks. Sexual Encounter Profile (SEP), which will ask question about each sexual attempt. Global Assessment Question, which will ask question at end of study if this app has improved erectile function. These questionnaires are conducted online for easy access and completion. There are no office visits. Registration to the study could be done at: http://eepurl.com/b3DcP1

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Erectile Dysfunction
Keywords
Erectile Dysfunction

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Utilization of Serenita for Relaxation
Arm Type
Experimental
Arm Description
Intervention is that Users continue to take their PDE-5 Inhibitor prior to sexual interaction and IN ADDITION Utilize the Serenita App daily and before any sexual encounters.
Intervention Type
Behavioral
Intervention Name(s)
Utilization of Serenita for Relaxation
Intervention Description
Users to use Serenita daily and before sexual interaction in order to assess stress and reduce it
Primary Outcome Measure Information:
Title
Global Assessment Profile measured by a survey
Description
If the treatment has improved their erectile function
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Index of Erectile Function measured by a survey
Description
if the treatment has improved erectile function
Time Frame
1 month

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male ages 18-55 years old Persistent mild to moderate ED on PDE5 inhibitors (Viagra, Cialis, Levitra, Stendra) Understand English Owns smartphone using either iPhone or Android Able to understand the use of "Serenita" app Willing to use Serenita app before sexual attempt Willing to complete all study questionnaires Willing to perform sexual attempt for at least once a week until end of study. Exclusion Criteria: On testosterone replacement therapy History of Peyronie's disease Significant cardiac history (uncontrolled hypertension, cardiac arrhythmia, coronary artery disease, coronary bypass surgery) Uncontrolled diabetes mellitus History of prostate cancer Poorly controlled, symptomatic, active medical problems (HIV, hepatitis, cancer, benign prostatic hypertrophy, alcohol or drug abuse, major depressive disorder) Neurological or psychiatric disorder that would compromise the patient's ability to give informed consent or adhere to the requirements of the protocol
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Oren Furst, Ph.D.
Email
oren@eco-fusion.com
Facility Information:
Facility Name
RMA
City
New York
State/Province
New York
ZIP/Postal Code
10025
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Oren Fuerst, Ph.D.
Email
oren@eco-fusion.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Links:
URL
http://www.eco-fusion.com
Description
Companys website

Learn more about this trial

Stress Management Using an App to Improve Response With PDE5 Inhibitors in Men With Erectile Dysfunction.

We'll reach out to this number within 24 hrs